.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ07_Beinaglutide.Beinaglutide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ07_Beinaglutide.Beinaglutide| name: | Beinaglutide | |
| ATC code: | A10BJ07 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 0.2 | mg |
| volume of distribution: | 8.5 | L |
| clearance: | 1.1 | L/h |
| other parameters in model implementation | ||
Beinaglutide is a recombinant human glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the management of type 2 diabetes mellitus. It mimics endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon secretion, delay gastric emptying, and promote satiety. Approved in China for type 2 diabetes, not approved in US or EU.
Estimated pharmacokinetic parameters based on class data and limited public sources; beinaglutide is typically studied in healthy or type 2 diabetic adult populations after subcutaneous administration.